Sunitinib is an inhibitor of the vascular endothelial growth factor and plateletderived growth factor receptors, and it has antitumor activity in metastatic renal cell carcinoma and gastrointestinal stromal tumors. To further investigate the fatigue associated with sunitinib therapy, thyroid function tests were performed on patients with metastatic renal cell carcinoma who were receiving sunitinib. Seventythree patients with metastatic renal cell carcinoma were treated with sunitinib at the Cleveland Clinic Taussig Cancer Center, and 66 of them had thyroid function test results available. Fifty-six (85%) of the 66 patients had one or more abnormality in their thyroid function test results, consistent with hypothyroidism, and 47 (84%) of the 56 patients with abnormal thyroid function tests had signs and/or symptoms possibly related to hypothyroidism. Thyroid hormone replacement was undertaken in 17 patients, and symptoms improved in nine of them. Thyroid function test abnormalities appear to be common in patients with metastatic renal cell carcinoma treated with sunitinib, and routine monitoring is warranted.
Sunitinib, an orally bioavailable oxindole, is small-molecule tyrosine kinase inhibitor for vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptors ( 1 , 2 ) . The antitumor activity of this agent was initially established in two, sequential single-arm phase II trials in patients with cytokine-refractory metastatic renal cell carcinoma. Objective response rates to sunitinib of approximately 40% and progression-free survival of 8.2 months were observed in these trials ( 3 , 4 ) . A subsequent, randomized phase III trial in untreated patients with metastatic renal cell carcinoma that compared sunitinib with interferon α observed a statistically significantly increased objective response rate (31% versus 6%, respectively; P <.001, Pearson chi-square test) and progressionfree survival (11 months versus 5 months, respectively; P <.001, unstratified log-rank test) ( 5 ) . In addition, activity of sunitinib against imatinib-resistant gastrointestinal stromal tumors led the Food and Drug Administration to approve sunitinib for treatment of imatinib-refractory gastrointestinal stromal tumor and advanced renal cell carcinoma in January 2006 ( 6 ) .
Common toxic effects in the renal cell carcinoma trials of sunitinib included fatigue, diarrhea, hand/foot syndrome, stomatitis, and hypertension. Fatigue was the most common and was often the doselimiting toxicity of sunitinib in patients with metastatic renal cell carcinoma. Fatigue in these patients prompted us to measure their thyroid function. In this report, we summarize the investigation of biochemical and clinical thyroid abnormalities in a cohort of patients with metastatic renal cell carcinoma treated with sunitinib. All patients, regardless of sex, were analyzed as a single cohort.
The medical records of patients with metastatic renal cell carcinoma enrolled in one of four institutional review boardapproved clinical trials of sunitinib monotherapy were reviewed. All patients signed a written informed consent form that was approved by the institutional review board. All patients received 50 mg of sunitinib orally daily for the fi rst 28 days of a 42-day cycle, with dose adjustment to 37.5 or 25 mg daily for toxicity, as required. Thyroid function test assessment (i.e., thyroid-stimulating hormone, T3, and T4 levels and free thyroxine index) was undertaken initially on some patients because the treating physicians suspected thyroid dysfunction and later on all patients prospectively. Thyroid hormone replacement therapy and/or more frequent thyroid function testing were undertaken at the discretion of the treating physician. Table 1 . Sixty-six patients had thyroid function test results available, initially obtained because of the clinical suspicion of treating physicians (n = 29) and later prospectively as routine laboratory assessment performed at baseline and on day 28 of every even-numbered cycle (n = 37). All patients with thyroid function test results had metastatic renal cell carcinoma. Patients in this study were treatment naive (n = 30) or had been treated with cytokine-based therapy (n = 30) or bevacizumab (Avastin, Genentech, South San Francisco, CA)-based therapy (n = 6) and then relapsed, as required by the eligibility criteria for the clinical trials in which they participated. Table 2 presents the thyroid function characteristics of the patients with metastatic renal cell carcinoma who were receiving sunitinib. Median thyroid-stimulating hormone at baseline was 2.56 mIU/L (range = 0.8 -34.8; a normal range is 0.40 -5.50 mIU/mL). Fifty-six (85%; 95% confidence interval (CI) = 74% to 92%) of the 66 patients with test results had one or more thyroid function test abnormalities. Such abnormalities were consistent with hypothyroidism in all patients and primarily included elevation of thyroid-stimulating hormone and decreased levels of T3 and, less commonly, decreases in T4 and/or of the free thyroxine index. Thyroid function test abnormalities were detected relatively early in the treatment course (median = at cycle 2), with a broad range. There were 43 males and 13 females with abnormal thyroid function test results, with a median age of 58 years (range = 23 -72 years). The de mographics and disease characteristics of patients with thyroid function test ab normalities were similar to those patients without such abnormalities. Two patients had a history of well-controlled hypothyroidism before the initiation of sunitinib treatment. The thyroid function tests of these two patients were consistent with more severe hypothyroidism during therapy with sunitinib. Among patients with abnormal thyroid function tests, signs and symptoms possibly related to hypothyroidism were found in 47 patients (84%; 95% CI = 72% to 92%), including fatigue, cold intolerance, anorexia, periorbital edema, fl uid retention, and changes in skin or hair. Thyroid hormone replacement was undertaken at the discretion of the treating physician (on the basis of the degree of biochemical abnormality and/or clinical symptoms) in 17 patients (30% of those with abnormal thyroid function tests, 95% CI = 19% to 44%) and resulted in resolution of biochemical abnormalities in all patients and improved symptoms in nine patients. Thyroglobulin antibodies were measured in 44 patients and were abnormal (i.e., >10.0 IU/mL) in 13 patients (30%, 95% CI = 17% to 45%; eight patients at baseline and fi ve patients after treatment). There was no association between the presence of thyroglobulin autoantibodies and either the incidence or severity of thyroid function test abnormalities. No other thyroid autoantibodies were measured. Among the 56 patients with abnormal thyroid function test results, 55 had tumor evaluation results available. The best response as defi ned by RECIST criteria was partial or complete response in 26 patients (47%, 95% CI = 34% to 61%). Among the 29 patients who did not achieve an objective response, 25 (44%) had stable disease and 4 (7%) had progressive disease.
In vitro and in vivo studies ( 8 -10 ) have found the expression of VEGF and VEGF receptor mRNA and protein in normal thyroid follicular cells, mediated at least in part 
CONTEXT AND CAVEATS

Prior knowledge
Fatigue was the most common toxic effect in patients with metastatic renal cell carcinoma in trials of sunitinib. Thyroid dysfunction has been associated with anticancer treatment for renal cell carcinoma.
Study type
Single clinic-based case series.
Contribution
Sunitinib treatment of patients with metastatic renal cell carcinoma can cause biochemical and clinical thyroid dysfunction. Symptoms improved in some patients after thyroid hormone replacement therapy.
Implications
Thyroid function test abnormalities are common in patients with metastatic renal cell carcinoma treated with sunitinib, and routine monitoring may be of value.
Limitations
The number of patients was small and there were no control subjects, so it could not be determined whether thyroid dysfunction was associated with outcome. by thyroid-stimulating hormone. Expression of VEGF protein and its receptor has not been well characterized in human thyroid tissue, and the dependence upon VEGF for normal thyroid function is unknown. It is possible that sunitinib, a VEGF receptor inhibitor, decreases thyroid function by preventing binding of VEGF to normal thyroid cells and/or by impairing thyroid blood fl ow, which results in thyroiditis. This hypothesis requires prospective testing and further examination of normal thyroid tissue in a cancer population. Sunitinibinduced hypothyroidism does not appear to be specifi c to patients with renal cell carcinoma because prior reports ( 11 , 12 ) in patients with gastrointestinal stromal tumor have also noted a substantial number of patients with hypothyroidism. Anticancer treatment in metastatic renal cell carcinoma has previously been associated with thyroid dysfunction ( 13 -15 ) . Development of thyroid autoantibodies has been associated with improved outcome in patients with metastatic renal cell carcinoma receiving immunotherapy, such as therapy with interleukin 2 or interferon α ( 13 , 14 ) . Although the mechanism of this potentially enhanced response remains unclear, it may involve a treatment-induced alteration of immune responsiveness and self-tolerance. The association of hypothyroidism without autoantibodies and improved clinical outcome in patients with metastatic renal cell carcinoma receiving cytokines has been observed in some, but not all, studies ( 15 , 16 ) . The objective response rates observed in patients with thyroid dysfunction in the present series approximate those observed in the general experience among sunitinibtreated patients with metastatic renal cell carcinoma. Thus, it cannot be determined from this small series of patients whether thyroid dysfunction is associated with clinical outcome in patients with metastatic renal cell carcinoma receiving sunitinib. This conclusion is tempered by certain study limitations, including the lack of baseline thyroid function tests in some patients, the relatively small number of total patients, and the high prevalence of biochemical hypothyroidism. Further examination of hypothyroidism, thyroid autoantibodies, and additional clinical outcome measures, such as tumor shrinkage and progression-free survival, are warranted to investigate a possible association.
In conclusion, sunitinib treatment in metastatic renal cell carcinoma patients can cause biochemical and clinical hypothyroidism. Routine monitoring of thyroid function tests is warranted, and replacement therapy should be undertaken as clinically indicated.
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